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Background: Cervical cancer ranks third in prevalence and fourth as cause of death in women worldwide. In Brazil,
17,540 women were diagnosed in 2012 with the disease. Persistent infection with high-risk HPV types is a necessary
condition for the development of pre-invasive and invasive cervical neoplasia. Currently, over 100 HPV types have
been identified, but HPV16 and 18 are recognized as the mayor culprits in cervical carcinogenesis. Our objective
was to assess the relationships between single- (ST) and multiple-type (MT) HPV infections with patients’ age and
lesion pathological status.
Methods: 328 patients with either squamous or glandular intraepithelial or invasive cervical lesion were selected.
All subjects were tested for HPV genotypes with reverse hybridization for 21 high- (hr-HPV) and 16 low-risk (lr-HPV)
probes. Prevalence of ST and MT HPV infections was compared across histological types and age strata.
Results: 287 (87%) women had at least one HPV type detected and 149 (52%) had MT infections. The most
prevalent HPV type was HPV16, present in 142 cases (49% of all HPV-positive cases), followed by HPV58, 52, 31, 35
and 33. HPV18, in single or multiple infections, occurred in 23 cases (8% of hr-HPV cases). Almost all glandular lesions were
associated with HPV16 and 18 alone. Multiple infections were significantly more prevalent in squamous than in glandular
lesion for HPV16 and 18 (P = 0.04 and 0.03 respectively). The prevalence of MT infections followed a bimodal distribution;
peaking in women younger 29 years and in those aged 50 to 59.
Conclusions: Our data indicate that prevention strategies for pre-invasive and invasive squamous lesions should be
focused on HPV16 and a few alpha-9 HPV types. It is clear to us that in young women, prophylaxis must cover a
large amalgam of HPV types beyond classic HPV16 and 18.
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Cervical cancer is the third most prevalent cancer
worldwide, being recognized as the fourth cause of
death due to cancer in women. It is the second more
prevalent type of cancer in women 44 years old or
younger [1]. Brazilian estimates for 2012 show that
roughly 17,540 women will be diagnosed with the dis-
ease in the country [2], with an estimated risk of 17
cases in 100,000 women.* Correspondence: derchain@fcm.unicamp.br
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reproduction in any medium, provided the orHigh-risk human Papillomavirus (hr-HPV) persistent
infection is considered the causal factor for pre invasive
and invasive cervical carcinoma [3]. More than 100 HPV
types have been identified and 40 are sexually transmit-
ted [4]. High-grade intraepithelial lesion and invasive
carcinoma, either squamous or glandular, are mostly as-
sociated with oncogenic HPV types included in alpha-9
(HPV 16, 31, 33, 35, 52, 58 and 67) and alpha-7 (HPV
18, 39, 45, 59, 68 and 70) species, considering that the
types belonging to a species have 80% of genetic similar-
ity [5]. Among these types, HPV 16 and 18 infections,
followed by HPV 31 and 45 are found in more than 80%
of cervical cancer specimens [6-9]. The prevalence ofl Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly credited.
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but HPV types from both species are associated with
stable and persistent infections [10]. In healthy women,
the prevalence of hr-HPV follows a bimodal distribution,
peaking in women aged 20 to 24 years and in those aged
50 to 54; multiple-type (MT) HPV infection is more
prevalent in women 30 years old or younger [11].
Single type (ST)-HPV 16 and 18 infections have been
unequivocally linked to high-grade lesions (either cervical
intraepithelial neoplasia (CIN) or in situ adenocarcinoma
(AIS)) and invasive squamous/glandular cervical cancer
(CC). MT-HPV has been observed in women with per-
sistent infections, but its relationship with cervical car-
cinogenesis has not been established [12]. Importantly,
there is no consensus whether MT-HPV infections har-
bouring HPV16/18 and other HPV types are associated
with higher risk of carcinogenesis than ST-HPV16/18 in-
fections [13]. In this study, we assessed the prevalence of
ST and MT-HPV infections in women with squamous
and glandular lesions of different age strata. Our objec-
tives were to evaluate whether ST and MT differed 1) in
its association with the type of the cervical lesion and 2)
according to the patients age.
Methods
Three-hundred twenty-eight Brazilian women with CIN,
AIS, squamous or glandular CC were included. Diagno-
ses were obtained with diathermic conization (either
LEEP or LLETZ). The women included in this study
were treated in two different urban centres: 118 cases at
the Department of Obstetrics and Gynaecology, Faculty
of Medical Sciences, State University of Campinas – UNI-
CAMP, Campinas, SP, Brazil and 210 at the Department of
Obstetrics and Gynaecology, Federal University of Goiás,
Goiânia, GO, Brazil. All women first attended a primary
screening program and were referred to the institutions
aforementioned because they had abnormal cytological
(Pap smear) results. Pap smear results were classified as:
inflammatory, squamous and glandular lesions. The
visit at the referral institutions comprised colposcopy
and collection of a second Pap test. This study was
approved by the respective Institution’s Internal Review
Boards of the two institutions (Comitê de Ética em
Pesquisa da Santa Casa de Misericórdia de Goiânia,
Goiânia, Goias, Brazil, and Comitê de Ética em Pesquisa
da Faculdade de Ciências Médicas da Unicamp, Campinas,
São Paulo, Brazil) and all selected women voluntarily
signed an informed consent form prior to enrolment.
Sample processing and DNA extraction
The cervical specimens for HPV-DNA were obtained with
an endocervical brush, and stored in a 1-mL tube contain-
ing Specimen Transport Medium (STM, QIAGEN Biotech-
nology Brazil Ltd.). Aliquots of 200 mL of the STM werecentrifuged for 10 minutes at 13,000 g. Supernatants were
immediately removed and the cellular pellets were split into
two parts and stored at −80°C until re-suspension in
200 μL of digestion solution (1 mM Tris, 200 mg of
proteinase K/μL, and 0.5% sodium dodecyl sulphate).
Digestion was performed at 55°C for 2 hours and was
followed by a 5-minute incubation at 95°C to inactivate
proteinase K. Nucleic acids were then purified by phenol-
chloroform extraction followed by ethanol precipitation.
After the DNA pellet had dried, it was dissolved in 100 μL
of Tris/EDTA (1 mM and 100 μM, respectively, pH 8.2).HPV-DNA testing
HPV DNA of samples was amplified using the Linear Array
HPV Test (LA, Roche Molecular Diagnostic, Pleasanton,
USA) for genotyping, based on the principle of DNA ampli-
fication by Polymerase Chain Reaction (PCR). This test de-
tects 21 hr-HPV probes (hr-HPV 16, 18, 26, 31, 33, 35, 39,
45, 51, 52, 53, 56, 58, 59, 66, 67, 68, 69, 73, 82 and IS39)
and 16 low-risk-HPV probes (HPV6, 11, 40, 42, 48, 54, 55,
57, 61, 62, 70, 71, 81, 83, 84 and CP6108). The amplification
profile was: activation of AmpliTaq Gold for 9 minutes at
95°C, denaturation for 1 minute at 95°C, annealing for 1 mi-
nute at 55°C and extension at 72°C for 1 minute, for a total
of 40 cycles, followed by a 5-minute terminal extension step
at 72°C. Amplicons were denatured in 0.4 N NaOH. In a
reverse-line blot assay, 40 μL of the denatured product were
added to 3 mL of hybridization buffer containing the HPV
genotypes and 2 concentrations of the β-globin probes,
immobilized on nylon strips. Positive hybridization was
detected by streptavidin-horseradish peroxidase-mediated
colour precipitation on the membrane at the probe line. In
specimens that were considered HPV-negative, the 2 β-
globin lines (high and low copies) either appeared at levels
comparable with those of positive controls or were re-
amplified. Only cases that had satisfactory β-globin levels
were included in the study. A HPV infection was classified
as single and multiple infections. Multiple infections in-
clude the association with hr and/or lr-HPV types.Cytology
All women had a cervical smear and the results of cer-
vical smears were classified in accordance with the 2001
Bethesda System [14]. Squamous cell abnormalities
less severe than invasive carcinoma were classified as
atypical squamous cells of undetermined significance
(ASC-US) and atypical squamous cells, cannot exclude
high-grade intraepithelial lesion (ASC-H), low-grade
squamous intraepithelial lesion (LSIL), and high-grade
squamous intraepithelial lesion (HSIL). For statistical
purposes, ASC-US was grouped with LSIL and ASC-H
with HSIL. Endocervical glandular cell abnormalities
less severe than invasive adenocarcinoma are classified
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with high-grade squamous intraepithelial lesion (AGC-
HSIL) and adenocarcinoma in situ (AIS).Histopathology
Cervical conization specimens, obtained with either Large
Loop Excision of the Transformation Zone (LLETZ) or
Loop Electrosurgical Excision Procedure (LEEP) were ob-
tained from all patients. The specimens were reviewed ac-
cording to the World Health Organization (WHO) criteria
[15] and were classified as: CIN1, CIN2, CIN3, invasive
squamous CC or in situ (AIS) and invasive adenocarcin-
oma. Three-hundred and five (93%) women had squa-
mous and 23 (7%) had glandular lesions. In women with
squamous lesions, 82 (25%) had CIN1, 61 (19%) CIN2,
159 (48%) CIN3, and 3 (<1%) had CC. In those with glan-
dular lesions, 13 (4%) had AIS and 10 (3%) had CC. For
statistical purposes, CIN 2, CIN3 and CC were grouped as
CIN2 or worse (223 cases (68%).Statistical analysis
Data were stored in electronic sheets and analysed with
the R Environment for Statistical Computing. P < 0.05
was considered significant. Fisher’s Exact tests were used
to compare the prevalence of single and multiple HPV
infection across histological (CIN1 vs. CIN2 or worse;
CIN2 or worse vs. glandular) strata. Chi-squares (and
Fisher’s Exact test where appropriate) were used to com-
pare the prevalence of single and multiple HPV infec-
tions in different age groups. Two-sided 95% confidence
intervals were calculated for the proportion of women
with MT infections displayed in Figure 1. 20-29 y 30
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Figure 1 Age stratified proportion of multiple-type HPV infections (95Results
Table 1 shows cytology results and age strata of the
women according to the final pathological diagnoses
(histology). For the majority of cases, the glandular and
squamous nature of the cytology and final pathological
diagnoses converged, as did the severity of the lesion.
Thirty-six per cent of the women were 29 years old or
younger, 49% were between 30 and 49 years old and 15%
were older than 50 years.
In Table 2, multiplicity of HPV infection is compared as
related to the final histology. Two-hundred eighty seven
(87%) women had at least one HPV detected and 149
(52%) had MT infections. HPV was not detectable in 26%
of CIN1, 10% of CIN2, 5% of CIN3 or cervical cancer and
22% of the glandular lesions. Fifty seven per cent of the
women with CIN1 and 53% of those with CIN2 had MT
infections; those CIN3 or cervical cancer had the same
number of single and multiple infection, when HPV was
detectable (p = 0.66). For women with glandular lesions, 13
(72%) had ST and only 5 (28%) had MT infections. Women
with squamous lesions had a significantly higher prevalence
of MT infections compared to women with glandular
lesions (p = 0.04). The most frequent HPV associations
were HPV 16/58 (19 cases), 16/52 (12 cases) and 16/18
(10 cases) (data not shown).
Table 3 shows the HPV types in ST and MT infec-
tions. HPV16 was detected in 142 cases (49% of all
HPV positive cases) and topped the prevalence rank in
both ST and MT groups. Infection by HPV58, 52, 31,
35 and 33 (all of them from alpha-9 species) followed.
HPV18 was detected in only 23 cases (8% of all hr-
HPV positive cases). ST HPV infections were less
prevalent than their MT counterparts containing the
same HPV type.-39 y 40-49 y 50-59 y  
34 41 14 7
40 22 17 4
4.1 34.9 54.8 36.4
% confidence intervals displayed in vertical bars).
Table 1 Women distribution according to cytology and age and histology results
Squamous lesions Glandular lesions
(Histology) (Histology)
TOTAL CIN1 CIN2 CIN3 CC AIS CC
n (%) n (%) n (%) n (%) n (%) n (%) n (%)
Cytology
Normal 37 (11) 19 (23) 6 (10) 12 (7) 0 0 0
Squamous lesions
ASC-US/LSIL 46 (14) 26 (32) 8 (13) 12 (8) 0 0 0
ASC-H/HSIL 169 (52) 22 (27) 37 (61) 103 (65) 3 (100) 3 (24) 1 (10)
Glandular lesions
AGC 65 (20) 15 (18) 9 (15) 27 (17) 0 8 (60) 6 (60)
AGC-HSIL 6 (2) 0 1 (1) 4 (2) 0 1 (8) 0
AIS 5 (1) 0 0 1 (1) 0 1 (8) 3 (30)
AGE (years)
≤ 19 12 (4) 5 (6) 3 (5) 3 (2) 1 (33) 0 0
20-29 107 (32) 35 (43) 22 (36) 48 (31) 0 1 (8) 1 (10)
30-39 87 (27) 22 (26) 16 (27) 42 (26) 1 (33) 5 (38) 1 (10)
40-49 74 (22) 13 (16) 15 (24) 40 (25) 0 4 (30) 2 (20)
50-59 36 (11) 7 (9) 3 (5) 19 (12) 0 2 (16) 5 (50)
≥ 60 12 (4) 0 2 (3) 7 (4) 1 (33) 1 (8) 1 (10)
TOTAL 328 (100) 82 (100) 61 (100) 159 (100) 3 (100) 13 (100) 10 (100)
CIN: cervical intraepithelial neoplasia, CC invasive cervical cancer, AIS: in situ adenocarcinoma, ASC-US/LSIL: atypical squamous cells of undetermined significance/
low-grade squamous intraepithelial lesion, ASC-H/HSIL: atypical squamous cells, cannot exclude high-grade intraepithelial lesion/high-grade squamous intraepithelial lesion,
AGC= atypical glandular cells, AGC-HSIL = atypical glandular cells associated with high-grade squamous intraepithelial lesion, AIS = in situ adenocarcinoma.
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prevalent HPV types according to histology. MT infec-
tions with either or both HPV16 and 18 were signifi-
cantly more prevalent in women with squamous than
in those with glandular lesions (p = 0.04 and 0.03 re-
spectively). Although the majority of CIN2 or worse
were associated with hr-HPV, six cases were associatedTable 2 Multiplicity of HPV infection according to
histopathology
HPV infection
Squamous lesions Glandular lesions
(AIS and CC)CIN1 CIN2 CIN3 and CC
n (%) n (%) n (%) n (%)
HPV detectable 60 (74) 55 (90) 154 (95) 18 (78)
Single type (ST) 26 (43) 22 (40) 77 (50) 13 (72)
Multiple type (MT) 34 (57) 33 (60) 77 (50) 5 (28)
HPV not
detectable
22 (26) 6 (10) 8 (5) 5 (22)
TOTAL 82
(100)
61
(100)
162 (100) 23 (100)
CIN: cervical intraepithelial neoplasia, CC: invasive cervical câncer, AIS: in situ
adenocarcinoma. HPV infections, whether single type or multiple type, did not
differ in women with CIN1 or CIN2 or worse (p = 0.66). The prevalence of MT
infection was significantly higher in women with CIN2 or worse compared to
those with glandular lesions (p = 0.04).with lr-HPV types only. All glandular lesions were as-
sociated with HPV16 and/or HPV18 (p = 0.04 and
p = 0.03, respectively), 13 of these in ST configuration.
Only five glandular lesions had MT HPV infection as-
sociated with them.
Figure 1 shows the proportion of MT HPV infections
as related to patient age. MT infections are the most
prevalent in women <29 years of age. At the strata age
of 40–49 years threshold, the prevalence of ST and MT
swaps in favour of ST infections. Another shift occurs at
50–59 years threshold, but the prevalence of MT infec-
tions is reduced again in older (≥60 years) women.
Discussion
In this study on 328 Brazilian women with pre-invasive
and invasive squamous and glandular lesions, 43% of the
women were detected with HPV16, but only 18.5% of
the women had HPV16 as ST infection. HPV16 was
followed in prevalence by other alpha-9 HPV types, and
HPV18 appeared only in the seventh position. Women
with squamous lesions had a higher proportion of MT
infections (most frequent associations were HPV 16/52,
16/58 and 16/18) compared to their counterparts with
glandular lesions, despite the small number of glandular
samples. Women with glandular lesions, by their turn,
Table 3 HPV types in single and multiple infections
HPV type ST infection MT infections TOTAL
n (%) n (%) n
hr-HPV
16 61 (43) 81 (57) 142
58 12 (27) 33 (73) 45
52 9 (26) 25 (74) 34
31 11 (34) 21 (66) 32
35 6 (22) 21 (78) 27
33 7 (26) 20 (74) 27
18 4 (17) 19 (83) 23
51 3 (14) 18 (86) 21
45 3 (21) 11 (79) 14
56 2 (20) 8 (80) 10
39 2 (20) 8 (80) 10
Other hr-HPV 10 (17) 49 (83) 59
Any hr-HPV 130 (47) 148 (53) 278
lr-HPV
6 3 (27) 5 (63) 8
11 1 (100) 0 1
Other lr-HPV 4 (8) 48 (92) 52
Any lr-HPV 8 (13) 53 (87) 61
Any HPV 138 (48) 149 (52) 287
All HPV types from single to multiple infections were computed individually,
for% calculation the denominator is represented by the total number of
infections (single or multiple) by type. From alfa-9 HPV group: 16, 31, 33, 35,
52 and 58. From alfa-7 HPV group: 18, 39 and 45. ST: single type, MT: multiple
type, hr-HPV: high risk HPV, lr-HPV: low-risk HPV.
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curve for MT infections shows prevalence peaks at a very
young (<29 years) age and in women 50–59 years of age.
In this mostly urban study, HPV infection with HPV16,
followed by HPV58, 52, 31, 35 and 33, were typical. The
most common HPV types are essentially from the alpha-
species, which are the most frequently detected types in
women with squamous lesions. Simonella et al. [16] found
similar trends in New Zealander women with CIN2 or
worse aged 20–69 years, for whom HPV16 was the most
prevalent HPV type detected (found in 44.1% of the
women) followed by HPV52 (16.8%), HPV31 (15.2%),
HPV33 (11.8%), HPV18 (11.3%) and HPV58 (10.1%).
Quint et al. [17] found that the most common HPV type
in women with CIN3 was HPV16, accounting for 56.9% of
ST and MT infections. This type followed by HPV31
(10.0%), 52 (8.4%) and 18 (4.6%). In their study, only two
CIN3 samples were positive for any single lr-HPV: HPV6
was detected in both cases as a ST infection. Kirschner
et al. [18] studied 266 Danish women with CIN2 and/or
CIN3 and seven with AIS. In that sample, 77.9% of the
women were diagnosed with a ST infection. The most
prevalent HPV types were: HPV16, detected >50% of thesample, followed by HPV33, 31, 18 and 52. Only 21.4%
were diagnosed with MT infections. We could identify
that the prevalence of HPV types in women with squa-
mous cervical lesions differs from that in women with
normal cervix. In a previous study with 1,509 Brazilian
healthy young women without cervical lesions of five dif-
ferent centres, aged 15 to 25 years, we found an overall
prevalence of HPV of 29.7%. The most prevalent HPV
type was HPV16, followed by HPV51, 52, 31 and 68 [19].
Among 8,656 healthy Danish women aged 20 to 29 years,
the prevalence of HPV types in decreasing rank was
HPV16 followed by HPV31, 52, 51, 33, 39, 45 and 56 [10].
In their study, women infected by alpha-9 HPV species
were at a higher risk of developing CIN2 or worse lesion
during a 10-year follow-up period [10].
In our study, squamous lesions were associated with
a higher prevalence of MT infections compared to
women with glandular lesions. It remains largely un-
known whether MT infections are associated with a
higher risk of developing squamous cervical lesions. In
our study, in spite of the limited sample size, we found
no difference in ST and MT prevalence comparing
women with CIN1 with those with CIN2 or worse. By
contrast, Pista et al. [12], studying Portuguese women,
found a significant association between MT infections and
disease severity. Argyri et al. [11] also found that MT in-
fections were significantly more common in women with
squamous intraepithelial lesions compared with healthy
women. In another study with women undergoing colpos-
copy for ASCUS/LSIL, Balbi et al. (2012) [20] concluded
that the infection with multiple HPV types is a significant
risk factor for high-grade CIN.
Simultaneous presence of multiple HPV genotypes
may be associated with a increased risk of high-grade
squamous lesions or invasive cancer than the presence
of single-type HPV infection. The classic study from
Trottier et al. (2006) [21] showed that infections with
multiple HPV may synergistically boost carcinogenesis.
In a recently published Brazilian study co-infecting HPV
genotypes occurred in a high proportion of sexually ac-
tive adolescents. Socio-demographic or sexual behaviour
factors associated with single HPV infection were similar
to those associated with multiple HPV types. There was
a higher risk of cytological abnormalities in women in-
fected with multiple HPV types suggesting a potential
role of co-infection in the natural history of HPV infec-
tion [22]. However, in another relatively recent study
[23], the difference between the duration of single and
that of concurrent multiple type-specific prevalent HPV
infections was not significant. Concurrent, prevalent de-
tection of additional HPV types did not change the like-
lihood of viral persistence.
In our sample, glandular lesions were associated essen-
tially with HPV16 or 18 ST infections. Quint et al. [17]
Table 4 Single and multiple type HPV infection status according to histopathological diagnoses
HPV
type
Type of
infection
CIN1 CIN2 or worse Glandular (AIS and CC) P1 P2
(n = 60) (n = 209) (n = 18) CIN 1 vs CIN
2 or worse
CIN 2 or worse
vs glandularN(%) N(%) N(%)
hr-HPV
16 Single 6 (10) 45 (22) 10 (55)
Multiple 13 (22) 64 (31) 4 (22) 0.46 0.04
58 Single 0 12 (6) 0
Multiple 8 (13) 24 (11) 1 (5) 0.08 1
52 Single 0 9 (4) 0
Multiple 5 (8) 19 (9) 1(5) 0.29 1
31 Single 4 (7) 7 (3) 0
Multiple 5 (8) 16 (8) 0 0.68 NC
35 Single 2 (3) 4 (2) 0
Multiple 7 (12) 13 (6) 1 (5) 1 0.98
33 Single 1 (<2) 6 (3) 0
Multiple 2 (3) 17 (8) 0 1 NC
18 Single 1 (<2) 0 3 (17)
Multiple 2 (3) 3 (<2) 4 (22) NC 0.03
51 Single 1 2 (1) 0
Multiple 7 (12) 10 (5) 1 (5) 1 1
45 Single 0 3 (<2) 0
Multiple 2 (3) 8 (4) 1 (5) 1 NC
56 Single 0 2 (1) 0
Multiple 3 (5) 6 (3) 0 1 NC
39 Single 1 (<2) 1 (<1) 0
Multiple 3 (5) 5 (2) 0 1 NC
Other Single 6 (10) 4 (2) 0
hr-HPV Multiple 13 (22) 34 (16) 1 (5) 0.07 1
Any hr- Single 22 (37) 95 (45) 13 (72)
HPV Multiple 34 (57) 110 (53) 5 (28) 0.36 <0.05
lr-HPV
6 Single 2 (3) 1 (<1) 0
Multiple 2 (3) 3 (<2) 0 1 NC
11 Single 0 1 (<1) 0
Multiple 0 0 0 NC NC
Others Single 6 (10) 4 (2) 0
lr-HPV Multiple 15 (25) 34 (16) 1 (5) 0.14 NC
Any HPV Single 26 (43) 99 (47) 13 (72)
Multiple 34 (57) 110 (53) 5 (28) 0.66 0.04
Prevalence was calculated by dividing the number of infected cases per HPV type by the number of women with the histopathological diagnosis. Totals surpass
100% because women with MT infections are counted at least twice. hr-HPV: high-risk HPV, lr-HPV: low-risk HPV, CIN: cervical intraepithelial neoplasia, AIS: in situ
adenocarcinoma, CC: invasive cervical cancer.
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of 70% of women with AIS or glandular-type CC. In the
series, HPV35 and 45 accounted for one case of AIS
(3.0%) and 10.9% of CC. A meta-analysis from 2007showed that HPV16 followed by 18 were the most com-
mon types in all continents. However, in Africa, Asia
and South/Central America, this preponderance is not
as marked as in Europe, North America and Australia.
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each continent, namely HPV31, 33, 35, 45, 52 and 58, al-
though their relative importance differed somewhat by
region [24]. In our study, HPV 58 and 52 were more fre-
quently detected than the other types, including HPV 18
which ranked only 7th. In the metanalysis [24], HPV18 was
significantly more prevalent in adeno/adenosquamous car-
cinoma than in squamous cell carcinoma, with the reverse
being true for HPV16, 31, 33, 52 and 58. In our sample,
stand-alone infection by HPV 16 or 18 were responsible for
most of the glandular lesions.
Another recent study examined the prevalence of
HPV type distribution in Brazilian women with and
without cervical lesions. From a total of 132 women
with amplified HPV-DNA the frequency of HPV HR-
types was 75%, with top appearing types being HPV16
(28%), followed by HPV18 (14.4%), HPV45 (7.6%),
HPV58 (6.8%), HPV66 (6.8%), HPV31 (3.8%) and
HPV33 (3.0%). The mean age of the 132 women were
39.5 years, ranging from 25 to 59 years of age. A sig-
nificantly lower proportion of LSIL and HSIL was
found among women infected by HPV16 and/or
HPV18 when compared to the ones infected by other
HR-types. Their data also showed that infection by
alpha-7 and alpha-9 species presented a significant dis-
tinct distribution by age at diagnosis respective to
women positive for other HPV types. However, separ-
ate comparisons among alpha-7 infections, alpha-9 in-
fection, and infections by other HPV types, did not
show a significant different distribution by age [25].
Another approach to the question was attempted by
Fernandes et al. (2010) who examined the HPV preva-
lence in archival samples obtained from patients with
cervical pre-malignant and malignant lesions from
Northeast Brazil. In that study, among the HPV-
positive samples, 86.7% had a single infection, while
13.3% had a double infection. These findings contrast
with ours, since we detected a higher prevalence of
MT infections in all lesion groups [26].
Our results may bear significance in the era of prophy-
lactic HPV vaccination. Both bivalent and quadrivalent
prophylactic HPV vaccines target hr-HPV16 and 18 and
had demonstrated different cross protection against
HPV31, 33, 45, 52 and 58, potentially diverting 90% of
cervical cancer risk. In addition to a new nonavalent vac-
cine against HPV16, 18, 31, 33, 45, 52 and 58 - now in
phase 3 testing - protection against the most prevalent
HPV types is in sight [27].
The main strength of this study is that all women
had a complete histological evaluation, giving to our
sample a strong reliability related to the gravity of the
cervical lesion. We also took care to assess all known
HPV types using reverse line blot hybridization assay,
which is an accurate and sensitive method. On theother hand, the sample is modest in size, especially
women with glandular lesions, which unfortunately is a
common situation in most recent papers on the subject.
Conclusions
Collectively, our data indicate that prevention strategies
for pre-invasive and invasive squamous lesions should
be focused on HPV16 and a few alpha-9 HPV types. It is
clear to us that in young women, prophylaxis must cover
a large amalgam of HPV types beyond classic HPV16
and 18. For the prevention of glandular lesions, ST HPV16
or 18 infections should be addressed, with other alpha-9 or
alpha-7 HPV types being of marginal importance.
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